Adjuvant Host-Directed Therapy with Types 3 and 5 but Not Type 4 Phosphodiesterase Inhibitors Shortens the Duration of Tuberculosis Treatment

Dose-Ranging Comparison of Rifampin and Rifapentine in Two Pathologically Distinct Murine Models of Tuberculosis

(2012) Ian M. Rosenthal et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Drug-drug interaction study to assess the effects of atorvastatin co-administration on pharmacokinetics and anti-thrombotic properties of cilostazol in male Wistar rats

(2012) Rahul Vats et al.   BIOPHARMACEUTICS & DRUG DISPOSITION

Successful Shortening of Tuberculosis Treatment Using Adjuvant Host-Directed Therapy with FDA-Approved Phosphodiesterase Inhibitors in the Mouse Model

(2012) Mamoudou Maiga et al.   PLoS One

Phosphodiesterase-4 Inhibition Combined with Isoniazid Treatment of Rabbits with Pulmonary Tuberculosis Reduces Macrophage Activation and Lung Pathology

(2011) Selvakumar Subbian et al.   AMERICAN JOURNAL OF PATHOLOGY

Sterilizing Activity of Novel TMC207- and PA-824-Containing Regimens in a Murine Model of Tuberculosis

(2011) Rokeya Tasneen et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

PDE4: A Novel Target in the Treatment of Chronic Obstructive Pulmonary Disease

(2011) J M Michalski et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Anti-asthmatic effect of ASP3258, a novel phosphodiesterase 4 inhibitor

(2011) Miki Kobayashi et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Phosphodiesterase 4 Inhibition Reduces Innate Immunity and Improves Isoniazid Clearance of Mycobacterium tuberculosis in the Lungs of Infected Mice

(2011) Mi-Sun Koo et al.   PLoS One

Phosphodiesterase-4 Inhibition Alters Gene Expression and Improves Isoniazid – Mediated Clearance of Mycobacterium tuberculosis in Rabbit Lungs

(2011) Selvakumar Subbian et al.   PLoS Pathogens

Targeting cancer with phosphodiesterase inhibitors

(2009) Rajkumar Savai et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS